Precigen | Evaluate

November 04, 2022

Abeona takes on Amryt – and more importantly, Krystal

Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.

Atara’s is the latest setback for a troubled field

Bayer dumps Atara, Precigen prepares for a fire sale and Tmunity struggles to find direction. Should investors still be excited about cell therapy?

June 12, 2019

Ziopharm stakes its reputation on personalised cell therapy

January 11, 2019

JP Morgan 2019 – Ziopharm celebrates its divorce with more promises

January 02, 2019

Pharma news over the Christmas period 2019

If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.

August 08, 2018

Is Spark really worth less than Crispr Therapeutics?

June 19, 2018

Ziopharm stalls its CAR yet again

March 06, 2018

Cytokine therapy focus – riding on Nektar’s coattails

December 14, 2017

Ash 2017 winners and losers – Déjà vu

November 02, 2017

Ash 2017 preview – Blueprint and Stemline celebrate

January 09, 2017

Interview – German Merck unveils its secret weapon

Load More